This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Puma Biotechnology Presents Positive PB272 Clinical Data At ASCO 2012 Annual Meeting

Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting. This trial was sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP), a clinical trials cooperative group supported by the National Cancer Institute (NCI).

A phase I dose-escalating study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER-2 positive breast cancer, NSABP FB-8.

The goal of the Phase I clinical trial was to determine the maximum tolerated dose of PB272 that could be given in combination with paclitaxel and trastuzumab to patients with metastatic HER-2 positive breast cancer. The study enrolled patients with confirmed HER-2 positive metastatic or locally advanced breast cancer, and documented disease progression following prior treatment with trastuzumab and taxane chemotherapy. Patients were administered PB272 at doses of 120 mg, 160 mg, 200 mg or 240 mg per day, respectively, in combination with paclitaxel given intravenously at a dose of 80 mg/m 2 on days 1, 8, and 15 of every 28 day cycle until disease progression and trastuzumab administered intravenously weekly using a 4 mg/kg loading dose, then 2 mg/kg weekly until disease progression.

The results of the study showed that of the 120 mg PB272 dose group, 1 of 3 patients developed a dose limiting toxicity (DLT) consisting of grade 3 diarrhea. Three additional patients were enrolled and none experienced DLT. At PB272 dose levels of 160 mg and 200 mg, there were no DLTs. At the PB272 240 mg dose level, 2 of 3 patients had DLTs involving grade 3 diarrhea. The efficacy results from the trial showed that for the 15 evaluable patients, 8 patients showed clinical activity. This included 1 patient with a complete response (CR) as per the RECIST criteria; 1 patient with non-measurable metastatic disease (skin metastases) who demonstrated a complete resolution of disease; 4 patients with a partial response as per the RECIST criteria; and 2 patients with ongoing stable disease, of whom 1 has been ongoing for over 4 months and 1 has been ongoing for over 10 months.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs